Patents Examined by Sharon X Wen
-
Patent number: 10357476Abstract: The use of a combination of carvedilol, metformin, evolocumab, and one or more statins to remove atheromas from coronary arteries and thereby treat coronary artery disease is disclosed. The method treats coronary artery disease by removing one or more atheromas from one or more coronary arteries of a patient by administering a therapeutically effective amount of: (a) carvedilol; (b) metformin; (c) evolocumab; and (d) one or more statins; or a pharmaceutically acceptable salt, prodrug, or derivative of one or more of (a)-(d). In some embodiments, the one or more statins comprise simvastatin. In some embodiments, the one or more statins comprise rosuvastatin. In some embodiments, the one or more statins comprise atorvastatin. In some embodiments, the one or more statins comprise pravastatin.Type: GrantFiled: November 10, 2018Date of Patent: July 23, 2019Inventor: Anis Ahmad
-
Patent number: 10344095Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.Type: GrantFiled: February 16, 2006Date of Patent: July 9, 2019Assignee: University of Kentucky Research FoundationInventor: Jayakrishna Ambati
-
Patent number: 10336834Abstract: A monoclonal antibody that binds to a phospholipase D4 (PLD4) protein, or a fragment containing an antigen-binding region thereof.Type: GrantFiled: March 2, 2018Date of Patent: July 2, 2019Assignee: SBI Biotech Co., Ltd.Inventors: Minkwon Cho, Tomohide Yamazaki, Mayuki Endo, Koji Ishida
-
Patent number: 10336832Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.Type: GrantFiled: July 23, 2014Date of Patent: July 2, 2019Assignee: Dyax Corp.Inventors: Daniel J. Sexton, Malini Viswanathan
-
Patent number: 10328120Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.Type: GrantFiled: June 28, 2016Date of Patent: June 25, 2019Assignees: Enzo Biochem, Inc., Enzo Therapeutics, Inc.Inventors: Joshua Rabbani, Xiaofeng Li, James J. Donegan
-
Patent number: 10301393Abstract: Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.Type: GrantFiled: June 3, 2016Date of Patent: May 28, 2019Assignee: Vaccinex, Inc.Inventors: Ernest S. Smith, Terrence L. Fisher
-
Patent number: 10280223Abstract: The object of the present invention is to provide an anti-canine PD-1 antibody or an anti-canine PD-L1 antibody, an agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody, a method for inhibiting binding between a canine PD-1 and a canine PD-L1 comprising using such an antibody, and a gene encoding such an antibody. An anti-canine PD-1 antibody that specifically binds to a canine PD-1 consisting of the amino acid sequence set forth in SEQ ID NO: 1 and an anti-canine PD-L1 antibody that specifically binds to a canine PD-L1 consisting of the amino acid sequence set forth in SEQ ID NO: 6 are produced. An agent for inhibiting binding between a canine PD-1 and a canine PD-L1 containing such an antibody is also produced.Type: GrantFiled: July 8, 2015Date of Patent: May 7, 2019Assignee: NIPPON ZENYAKU KOGYO CO., LTD.Inventors: Takuya Mizuno, Kazuha Shosu
-
Patent number: 10265401Abstract: The present invention relates generally to stable formulations comprising CTLA4Ig molecules, including lyophilized, and liquid formulations for administration via various routes including, for example, routes such as intravenous (IV) and subcutaneous (SC) for treating immune system diseases and tolerance induction.Type: GrantFiled: March 10, 2016Date of Patent: April 23, 2019Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Manisha P Desai, Charles E Dahlheim, Sunita Borsadia, Vijay H Naringrekar, Rajesh Babulal Gandhi, Manoj Nerurkar
-
Patent number: 10259885Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for PCSK9. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-PCSK9 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-PCSK9 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-PCSK9 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with PCSK9.Type: GrantFiled: December 22, 2015Date of Patent: April 16, 2019Assignee: ALDERBIO HOLDINGS LLCInventors: Andrew Lawrence Feldhaus, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Ethan Wayne Ojala, Brian Robert Kovacevich, Katie Olson Anderson, Pei Fan, Jens Billgren, Erica Ann Stewart, Corinne C. Akatsuka, Patricia Dianne McNeill, Danielle Marie Mitchell, Daniel Scott Allison, John A. Latham
-
Patent number: 10251906Abstract: In an aspect, the invention relates to compositions, methods, and kits for inducing apoptosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: March 11, 2014Date of Patent: April 9, 2019Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Jindrich Henry Kopecek, Jiyuan Yang, Te-Wei Chu
-
Patent number: 10232016Abstract: The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.Type: GrantFiled: September 3, 2015Date of Patent: March 19, 2019Assignees: Acorda Therapeutics, Inc., Beth Israel Deaconess Medical Center, Inc., The Brigham and Women's Hospital, Inc.Inventors: Mark Marchionni, Ralph Kelly, Beverly Lorell, Douglas B. Sawyer
-
Patent number: 10222382Abstract: In subjects with hypertension, increases in intima-media thickness (IMT) at four years were less in subjects also having high autoantibodies particularly IgM, to phosphorylcholine. The presence or absence of autoantibodies, particularly IgM, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases. A method to determining antibodies, particularly IgM antibodies, toward phosphorylcholine is proposed in this invention to identify subjects at risk of developing ischemic cardiovascular diseases. Animal experiments show that medium to high levels of antibodies, particularly IgM antibodies, can be detected in plasma after active immunization with a keyhole limpet hemocyanin (KLH)-phosphorylcholine conjugate.Type: GrantFiled: January 15, 2014Date of Patent: March 5, 2019Assignee: ATHERA BIOTECHNOLOGIES ABInventors: Ulf De Faire, Johan Frostegård
-
Patent number: 10214593Abstract: Disclosed are an anti-idiotype antibody that specifically binds to an idiotope site of an anti-c-Met antibody, the use of the anti-idiotype antibody for detecting the anti-c-Met antibody, and methods, polypeptides, polynucleotides, compositions, and vaccines related thereto.Type: GrantFiled: April 2, 2014Date of Patent: February 26, 2019Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Soo Yeon Jung, Yun Jeong Song, Mi Young Cho, Han Na Choi
-
Patent number: 10201606Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.Type: GrantFiled: November 25, 2015Date of Patent: February 12, 2019Assignee: MILTENYI BIOTEC GMBHInventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
-
Patent number: 10160801Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: GrantFiled: June 27, 2018Date of Patent: December 25, 2018Assignee: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Patent number: 10139420Abstract: The present invention relates to methods for determining the risk of severe complications in hemolytic diseases. The present invention relates to a method for determining whether a patient suffering from sickle cell disease is at risk for a vaso-occlusive crisis comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles. The present invention also relates to a method for a method the severe complication in hemolytic diseases comprising the steps consisting of i) determining the level of cell microparticles in a blood sample obtained from said patient and ii) determining the level of heme and/or hemoglobin contained in said cell microparticles.Type: GrantFiled: March 9, 2012Date of Patent: November 27, 2018Assignees: ISNERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique—Hopitaux de ParisInventors: Olivier Blanc-Brude, Pierre-Louis Tharaux, Chantal Boulanger, Sylvain Lejeune, Francois Lionnet
-
Patent number: 10111953Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.Type: GrantFiled: May 29, 2014Date of Patent: October 30, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Gary Swergold, William J. Sasiela, Robert C. Pordy
-
Patent number: 10106615Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.Type: GrantFiled: May 23, 2013Date of Patent: October 23, 2018Assignee: E. R. SQUIBB & SONS, L.L.C.Inventors: Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan Korman, Josephine M. Cardarelli
-
Patent number: 10093719Abstract: It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.Type: GrantFiled: March 28, 2014Date of Patent: October 9, 2018Assignee: KYOWA HAKKO KIRIN CO., LTDInventors: Nobuaki Takahashi, Hideaki Yoshida
-
Patent number: 10076571Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.Type: GrantFiled: September 12, 2012Date of Patent: September 18, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Gary Swergold